We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Adagene Inc. Sponsored ADR is a member of our Medical group, which includes 975 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ADAG's full-year earnings has moved 12.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ADAG has returned 10.6% so far this year. Meanwhile, the Medical sector has returned an average of -1.4% on a year-to-date basis. As we can see, Adagene Inc. Sponsored ADR is performing better than its sector in the calendar year.
ANI Pharmaceuticals (ANIP - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 72.5%.
Over the past three months, ANI Pharmaceuticals' consensus EPS estimate for the current year has increased 12.5%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 485 individual stocks and currently sits at #93 in the Zacks Industry Rank. Stocks in this group have gained about 5.2% so far this year, so ADAG is performing better this group in terms of year-to-date returns. ANI Pharmaceuticals is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adagene Inc. Sponsored ADR and ANI Pharmaceuticals as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Adagene Inc. Sponsored ADR is a member of our Medical group, which includes 975 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ADAG's full-year earnings has moved 12.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ADAG has returned 10.6% so far this year. Meanwhile, the Medical sector has returned an average of -1.4% on a year-to-date basis. As we can see, Adagene Inc. Sponsored ADR is performing better than its sector in the calendar year.
ANI Pharmaceuticals (ANIP - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 72.5%.
Over the past three months, ANI Pharmaceuticals' consensus EPS estimate for the current year has increased 12.5%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 485 individual stocks and currently sits at #93 in the Zacks Industry Rank. Stocks in this group have gained about 5.2% so far this year, so ADAG is performing better this group in terms of year-to-date returns. ANI Pharmaceuticals is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Adagene Inc. Sponsored ADR and ANI Pharmaceuticals as they could maintain their solid performance.